Patent ID: 11891644
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of producing T cells having reduced surface fucosylation, the method comprising:
culturing T cells in the presence of an effective amount of a fucose analog in a cell culture medium; wherein, said fucose analog is selected from the group consisting of formulae (I) and (II):, , or a pharmaceutically acceptable salt or solvate form thereof, wherein each of formula (I) or (II) can be the alpha or beta anomer or the corresponding aldose form;
R2 is halogen; each of R1, R3, and R4 is independently —OH or a hydrolyzable ester group; and R5 is —CH3, or
each of R1, R2, R3, and R4 is independently —OH or a hydrolyzable ester group; and R5 is —C≡CH;
and

wherein said T cells cultured in the presence of the effective amount of said fucose analog have at least about 80% reduced surface fucosylation relative to T cells cultured in the absence of said fucose analog; and wherein the T cells having reduced surface fucosylation are configured to be used in an adoptive cell therapy.